Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2

Sharon Min Qi Chee, Jantana Wongsantichon, Quah Soo Tng, Robert Robinson, Thomas L. Joseph, Chandra Verma, David P. Lane, Christopher J. Brown, Farid J. Ghadessy

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 Å crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.

Original languageEnglish
Article numbere104914
JournalPloS one
Volume9
Issue number8
DOIs
Publication statusPublished - Aug 12 2014
Externally publishedYes

Fingerprint

antagonists
peptides
Peptides
staples
Hydrocarbons
hydrocarbons
Tumors
mutation
Mutation
Molecules
hydrophobic bonding
crystal structure
Hydrophobic and Hydrophilic Interactions
Refractory materials
Plasticity
Neoplasms
Cell Death
Crystal structure
Cells
death

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chee, S. M. Q., Wongsantichon, J., Soo Tng, Q., Robinson, R., Joseph, T. L., Verma, C., ... Ghadessy, F. J. (2014). Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. PloS one, 9(8), [e104914]. https://doi.org/10.1371/journal.pone.0104914

Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. / Chee, Sharon Min Qi; Wongsantichon, Jantana; Soo Tng, Quah; Robinson, Robert; Joseph, Thomas L.; Verma, Chandra; Lane, David P.; Brown, Christopher J.; Ghadessy, Farid J.

In: PloS one, Vol. 9, No. 8, e104914, 12.08.2014.

Research output: Contribution to journalArticle

Chee, SMQ, Wongsantichon, J, Soo Tng, Q, Robinson, R, Joseph, TL, Verma, C, Lane, DP, Brown, CJ & Ghadessy, FJ 2014, 'Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2', PloS one, vol. 9, no. 8, e104914. https://doi.org/10.1371/journal.pone.0104914
Chee SMQ, Wongsantichon J, Soo Tng Q, Robinson R, Joseph TL, Verma C et al. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. PloS one. 2014 Aug 12;9(8). e104914. https://doi.org/10.1371/journal.pone.0104914
Chee, Sharon Min Qi ; Wongsantichon, Jantana ; Soo Tng, Quah ; Robinson, Robert ; Joseph, Thomas L. ; Verma, Chandra ; Lane, David P. ; Brown, Christopher J. ; Ghadessy, Farid J. / Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2. In: PloS one. 2014 ; Vol. 9, No. 8.
@article{4419e93b27f0433e904197b2a2e1a479,
title = "Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2",
abstract = "As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 {\AA} crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.",
author = "Chee, {Sharon Min Qi} and Jantana Wongsantichon and {Soo Tng}, Quah and Robert Robinson and Joseph, {Thomas L.} and Chandra Verma and Lane, {David P.} and Brown, {Christopher J.} and Ghadessy, {Farid J.}",
year = "2014",
month = "8",
day = "12",
doi = "10.1371/journal.pone.0104914",
language = "English",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2

AU - Chee, Sharon Min Qi

AU - Wongsantichon, Jantana

AU - Soo Tng, Quah

AU - Robinson, Robert

AU - Joseph, Thomas L.

AU - Verma, Chandra

AU - Lane, David P.

AU - Brown, Christopher J.

AU - Ghadessy, Farid J.

PY - 2014/8/12

Y1 - 2014/8/12

N2 - As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 Å crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.

AB - As key negative regulator of the p53 tumour suppressor, Mdm2 is an attractive therapeutic target. Small molecules such as Nutlin have been developed to antagonise Mdm2, resulting in p53-dependent death of tumour cells. We have recently described a mutation in Mdm2 (M62A), which precludes binding of Nutlin, but not p53. This Nutlin-resistant variant is not, however, refractory to binding and inhibition by stapled peptide antagonists targeting the same region of Mdm2. A detailed understanding of how stapled peptides are recalcitrant to Mdm2 mutations conferring Nutlin-resistance will aid in the further development of potent Mdm2 antagonists. Here, we report the 2.00 Å crystal structure of a stapled peptide antagonist bound to Nutlin resistant Mdm2. The stapled peptide relies on an extended network of interactions along the hydrophobic binding cleft of Mdm2 for high affinity binding. Additionally, as seen in other stapled peptide structures, the hydrocarbon staple itself contributes to binding through favourable interactions with Mdm2. The structure highlights the intrinsic plasticity present in both Mdm2 and the hydrocarbon staple moiety, and can be used to guide future iterations of both small molecules and stapled peptides for improved antagonists of Mdm2.

UR - http://www.scopus.com/inward/record.url?scp=84905841311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905841311&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0104914

DO - 10.1371/journal.pone.0104914

M3 - Article

C2 - 25115702

AN - SCOPUS:84905841311

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e104914

ER -